RxDoctor Payments Data

Karl Dauphinais, MD

Internal Medicine · Farmington, CTNPI 1548467897

Payments from drug & device makers

$942in general payments, 2019–2025

Across 36 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$485
  • Pfizer$67
  • Novo Nordisk$50
  • Avanir Pharmaceuticals, Inc.$49
  • Johnson & Johnson$46
  • GSK$43
  • plus $201 from 10 others

What the payments were for

  • Food & beverage$942100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$942 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,318
Medicare patients
47
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate52$66,484
EliquisApixaban300$45,600
TrulicityDulaglutide18$18,767
VraylarCariprazine Hcl52$18,675
XareltoRivaroxaban128$18,606
LokelmaSodium Zirconium Cyclosilicate33$18,311
Bydureon BciseExenatide Microspheres19$16,949
Breo ElliptaFluticasone/Vilanterol30$13,284
Spiriva HandihalerTiotropium Bromide22$12,450
Sevelamer Carbonate17$9,078
JanuviaSitagliptin Phosphate52$7,711
LinzessLinaclotide13$7,672
TradjentaLinagliptin52$7,080
BrilintaTicagrelor52$6,006
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$5,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$45,600300 claims
AbbVieVraylar, Linzess$11$26,34765 claims
AstraZenecaLokelma, Brilinta$11$24,31685 claims
GSKBreo Ellipta, Anoro Ellipta$43$18,88346 claims
Johnson & JohnsonXarelto$46$18,606128 claims
Boehringer IngelheimTradjenta, Jardiance$19$8,83264 claims
MerckJanuvia$32$7,71152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →